ERNALIX Med
0808.336.533 · rovalta.com · 24/09/2026
ACTIVE
ERNALIX Med
Financial year 2023 · closed on 31/12/2023
Net result
43,6 k €
-0.9% YoY
Gross margin
152,6 k €
-6.9% YoY
Equity
328,9 k €
+15.3% YoY
Overview
What does ERNALIX Med do?
ERNALIX Med is a Private company with limited liability incorporated in 2008. Its main activity is: General medical practice activities. Its registered office is in Charleroi.
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0808.336.533
Incorporation
10/12/2008
Legal form
Private company with limited liability
Registered office
Rue Isaac 6
6000 Charleroi · WallonieSee on map
6000 Charleroi · WallonieSee on map
Contributed capital
12 400,00 €
Latest accounts
31/12/2023
Activities (NACE)
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 14 financial years
| 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||
| Gross margin | 152,6 k € | -6.9% | 163,9 k € | +70.8% | 96 k € | +35.6% | 70,8 k € | -46.8% | 133 k € | +13.8% | 116,9 k € | -0.7% | 117,8 k € | +15.6% | 101,9 k € | -17.4% | 123,3 k € | +53.7% | 80,2 k € | -35.0% | 123,4 k € | +51.9% | 81,2 k € | +20.9% | 67,2 k € | -28.0% | 93,3 k € |
| EBITDA | 146 k € | -10.2% | 162,7 k € | +76.9% | 92 k € | +34.3% | 68,4 k € | -48.2% | 132,2 k € | +14.2% | 115,8 k € | +4.8% | 110,5 k € | +9.6% | 100,8 k € | -17.6% | 122,4 k € | +54.7% | 79,1 k € | -35.4% | 122,5 k € | +56.7% | 78,2 k € | +17.2% | 66,7 k € | -28.0% | 92,6 k € |
| Operating result | 127 k € | -6.0% | 135,1 k € | +112% | 63,7 k € | +65.1% | 38,6 k € | -57.5% | 90,7 k € | +41.5% | 64,1 k € | +9.6% | 58,5 k € | +9.2% | 53,6 k € | -29.4% | 76 k € | +101% | 37,8 k € | -53.6% | 81,4 k € | +114% | 38 k € | +27.0% | 29,9 k € | -45.4% | 54,8 k € |
| Net result | 43,6 k € | -0.9% | 44 k € | +1818% | -2,6 k € | +59.9% | -6,4 k € | -122% | 29,1 k € | +421% | 5,6 k € | +151% | -10,8 k € | -637% | -1,5 k € | -115% | 10,1 k € | -42.4% | 17,6 k € | -65.9% | 51,5 k € | +109% | 24,6 k € | +41.6% | 17,4 k € | -53.1% | 37 k € |
| Balance sheet | |||||||||||||||||||||||||||
| Equity | 328,9 k € | +15.3% | 285,2 k € | +17.9% | 242 k € | -1.5% | 245,6 k € | +27.8% | 192,1 k € | +17.4% | 163,7 k € | +3.5% | 158,1 k € | -6.4% | 169 k € | -0.9% | 170,5 k € | +6.3% | 160,3 k € | +12.3% | 142,8 k € | +56.3% | 91,3 k € | +36.8% | 66,7 k € | +35.2% | 49,4 k € |
| Total assets | 373 k € | +12.2% | 332,5 k € | +24.2% | 267,6 k € | -15.1% | 315,4 k € | -0.7% | 317,5 k € | -3.2% | 328 k € | -13.7% | 380,1 k € | -6.7% | 407,5 k € | -3.8% | 423,8 k € | +4.7% | 404,7 k € | +3.1% | 392,6 k € | +5.5% | 372,3 k € | +0.3% | 371,3 k € | +51.4% | 245,2 k € |
| Cash | 7,3 k € | -64.4% | 20,6 k € | -65.6% | 59,9 k € | -14.2% | 69,8 k € | +313% | 16,9 k € | +134131% | 12,6 € | -99.9% | 12,2 k € | -42.0% | 21 k € | -2.2% | 21,4 k € | +0.8% | 21,3 k € | -35.3% | 32,8 k € | +249% | 9,4 k € | +5463% | 169 € | -18.0% | 206 € |
| Debts | 44,2 k € | -6.5% | 47,3 k € | +84.4% | 25,6 k € | -63.3% | 69,8 k € | -42.9% | 122,2 k € | -25.6% | 164,3 k € | -26.0% | 222 k € | -6.9% | 238,5 k € | -5.8% | 253,3 k € | +5.5% | 240,2 k € | -3.9% | 249,9 k € | -11.1% | 281 k € | -7.7% | 304,6 k € | +55.6% | 195,8 k € |
Estimate
Indicative valuation
As an indication, this company is worth
between 500 k€ and 1 M€
See the valuationGovernance
Board of directors
Seen on filing of 31/12/2023 · 1 active
Active mandates
Eric Cavatorta
ActiveFinancials
Annual accounts
Full financial information
| 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2018 | 01/01/2017 |
| Closing of the financial year | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2018 | 31/12/2017 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 02/06/2025 | 29/11/2023 | 14/10/2022 | 30/09/2022 | 30/08/2019 | 23/08/2018 |
| General meeting | 29/06/2024 | 24/06/2023 | 25/06/2022 | 26/06/2021 | 29/06/2019 | 30/06/2018 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
14 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2023 | 29/06/2024 | 02/06/2025 | French | |
| Micro model | 31/12/2022 | 24/06/2023 | 29/11/2023 | French | |
| Micro model | 31/12/2021 | 25/06/2022 | 14/10/2022 | French | |
| Micro model | 31/12/2020 | 26/06/2021 | 30/09/2022 | French | |
| Micro model | 31/12/2018 | 29/06/2019 | 30/08/2019 | French | |
| Micro model | 31/12/2017 | 30/06/2018 | 23/08/2018 | French | |
| Micro model | 31/12/2016 | 24/06/2017 | 26/09/2017 | French | |
| Abridged model | 31/12/2015 | 25/06/2016 | 31/08/2016 | French | |
| Abridged model | 31/12/2014 | 27/06/2015 | 21/08/2015 | French | |
| Abridged model | 31/12/2013 | 28/06/2014 | 19/08/2014 | French | |
| Abridged model | 31/12/2012 | 29/06/2013 | 27/08/2013 | French | |
| Abridged model | 31/12/2011 | 30/06/2012 | 20/09/2012 | French | |
| Abridged model | 31/12/2010 | 25/06/2011 | 22/08/2011 | French | |
| Abridged model | 31/12/2009 | 26/06/2010 | 03/09/2010 | French |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 500 k€ and 1 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2023 · 1 active
Active mandates
Eric Cavatorta
ActiveShareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2023Annual accounts 202343,6 k €↓
- 2022Annual accounts 202244 k €↑
- 2021Annual accounts 2021-2,6 k €↑
- 2020Annual accounts 2020-6,4 k €↓
- 2020Name changeErnalix
- 2018Annual accounts 201829,1 k €↑
- 2017Annual accounts 20175,6 k €↑
- 2016Annual accounts 2016-10,8 k €↓
- 2015Annual accounts 2015-1,5 k €↓
- 2014Annual accounts 201410,1 k €↓
- 2013Annual accounts 201317,6 k €↓
- 2012Annual accounts 201251,5 k €↑
- 2011Annual accounts 201124,6 k €↑
- 2010Annual accounts 201017,4 k €↓
- 2009Annual accounts 200937 k €
- 2009Name changeERNALIX Med
- 10/12/2008IncorporationPrivate company with limited liability